Does life expectancy of patients with hepatocellular carcinoma only depend on the upfront treatment?

Diagn Interv Imaging. 2023 Apr;104(4):165-166. doi: 10.1016/j.diii.2023.01.004. Epub 2023 Jan 28.

Authors

David Fuks¹, Ugo Marchese²

Affiliations

¹ Department of Hepato-Pancreatic-Biliary and Endocrine Surgery, Hopital Cochin, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; Université Paris Cité, 75006 Paris, France. Electronic address: david.fuks@aphp.fr.
² Department of Hepato-Pancreatic-Biliary and Endocrine Surgery, Hopital Cochin, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; Université Paris Cité, 75006 Paris, France.

PMID: 36717337
DOI: 10.1016/j.diii.2023.01.004

No abstract available

Keywords: Chemoembolization; Hepatocellular carcinoma; Long-term prognosis; Radiofrequency ablation; Survival rate.

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Hepatocellular* / pathology
Catheter Ablation*
Chemoembolization, Therapeutic*
Combined Modality Therapy
Humans
Life Expectancy
Liver Neoplasms* / diagnostic imaging
Liver Neoplasms* / pathology
Liver Neoplasms* / therapy
Retrospective Studies
Survival Rate
Treatment Outcome